To Market, To Market—2012
Authors:
- Joanne BronsonJBJoanne Bronson
- Amelia BlackABAmelia Black
- T. G. Murali DharTDT. G. Murali Dhar
- Bruce A. EllsworthBEBruce A. Ellsworth
- J. Robert MerrittJMJ. Robert Merritt
- 1 January 2013
- book chapter
- Published by Elsevier
- p. 471-546
Abstract
No abstract availableThis publication has 168 references indexed in Scilit:
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyNew England Journal of Medicine, 2012
- Efficacy and Safety of Vismodegib in Advanced Basal-Cell CarcinomaNew England Journal of Medicine, 2012
- Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I studyBritish Journal of Cancer, 2012
- Targeting Chemokine Receptor CCR4 in Adult T-Cell Leukemia-Lymphoma and Other T-Cell LymphomasCurrent Hematologic Malignancy Reports, 2012
- Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast CancerNew England Journal of Medicine, 2012
- Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trialThe Lancet, 2011
- A CFTR Potentiator in Patients with Cystic Fibrosis and theG551DMutationNew England Journal of Medicine, 2011
- Structure−Activity Relationship for Thiohydantoin Androgen Receptor Antagonists for Castration-Resistant Prostate Cancer (CRPC)Journal of Medicinal Chemistry, 2010
- Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770Proceedings of the National Academy of Sciences, 2009
- A phase I dose-finding and pharmacokinetic study of subcutaneous semisynthetic homoharringtonine (ssHHT) in patients with advanced acute myeloid leukaemiaBritish Journal of Cancer, 2006